Therapy for CPPD: Options and Evidence

Therapy for CPPD: Options and Evidence Purpose of Review Current evidence and accumulated experience for the management of calcium pyrophosphate deposition disease (CPPD) are presented. Recent Findings Contrary to other rheumatic inflammatory conditions that account for high interest and growing research, advances in treating CPPD are still very limited and mostly derive from those achieved in gout. Summary Once formed, calcium pyrophosphate crystals cannot be dissolved; therefore, management relies on the control of crystal-derived inflammation. Besides classical agents—such as colchicine, glucocorticoids, or NSAIDs—the use of targeted therapies, mostly against interleukin-1, has provided a relevant relief for refractory CPPD patients in recent years. Meanwhile, former enthusiasm about conventional disease-modifying agents such as methotrexate is currently controversial. . . . . . Keywords Calcium pyrophosphate Chondrocalcinosis Therapy Colchicine Methotrexate Anakinra Introduction with early severe osteoarthritis (OA)—occur in younger peo- ple (in familial or sporadic forms). The usual clinical presen- Even though calcium pyrophosphate deposition disease tation is that of an acute arthritis, most frequently affecting the (CPPD) [1] is a common disease and a frequent cause of visits knee joint and clinically similar to gout. This similarity gave to the emergency services, it has received scant attention in the rise to the name “pseudogout.” Though inflammatory symp- http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Rheumatology Reports Springer Journals

Therapy for CPPD: Options and Evidence

Loading next page...
 
/lp/springer_journal/therapy-for-cppd-options-and-evidence-MibgXN9ojY
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer Science+Business Media, LLC, part of Springer Nature
Subject
Medicine & Public Health; Rheumatology
ISSN
1523-3774
eISSN
1534-6307
D.O.I.
10.1007/s11926-018-0739-z
Publisher site
See Article on Publisher Site

Abstract

Purpose of Review Current evidence and accumulated experience for the management of calcium pyrophosphate deposition disease (CPPD) are presented. Recent Findings Contrary to other rheumatic inflammatory conditions that account for high interest and growing research, advances in treating CPPD are still very limited and mostly derive from those achieved in gout. Summary Once formed, calcium pyrophosphate crystals cannot be dissolved; therefore, management relies on the control of crystal-derived inflammation. Besides classical agents—such as colchicine, glucocorticoids, or NSAIDs—the use of targeted therapies, mostly against interleukin-1, has provided a relevant relief for refractory CPPD patients in recent years. Meanwhile, former enthusiasm about conventional disease-modifying agents such as methotrexate is currently controversial. . . . . . Keywords Calcium pyrophosphate Chondrocalcinosis Therapy Colchicine Methotrexate Anakinra Introduction with early severe osteoarthritis (OA)—occur in younger peo- ple (in familial or sporadic forms). The usual clinical presen- Even though calcium pyrophosphate deposition disease tation is that of an acute arthritis, most frequently affecting the (CPPD) [1] is a common disease and a frequent cause of visits knee joint and clinically similar to gout. This similarity gave to the emergency services, it has received scant attention in the rise to the name “pseudogout.” Though inflammatory symp-

Journal

Current Rheumatology ReportsSpringer Journals

Published: Apr 19, 2018

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off